SCHEMBL614840

SCHEMBL614840

CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.59
DGKA P23743 1/20 0.43
GAA P10253 1/20 0.43
PRKCA P17252 5/20 0.42
LMNA P02545 2/20 0.41
PAM P19021 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15299916 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL3794062 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL2340491 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL17734434 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL3787448 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL226443 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL9747148 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL3782110 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL18473229 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA
SCHEMBL14525067 1.00 NAAA (0.59) NAAADGKAGAAPRKCALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221968-A1 TREATMENTS AND METHODS FOR INCREASING DOPAMINE UNIV OXFORD INNOVATION LTD (GB) 2025-07-10 US claimed
EP-4493171-A1 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) 2025-01-22 EP claimed
WO-2023175357-A1 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-09-21 WO claimed
US-8980923-B2 Compositions and methods for selective inhibition of nicotine acetylcholine receptors UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-03-17 US claimed
US-20120329783-A1 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-12-27 US claimed
US-7531555-B2 Compositions and methods for selective inhibition of nicotine acetylcholine receptors UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2009-05-12 US claimed
US-20090062339-A1 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-03-05 US claimed
US-20050119309-A1 Compositions and methods for selective inhibition of nicotine acetylcholine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-02 US claimed
WO-2005032479-A2 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS UNVIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2005-04-14 WO claimed
US-20250221968-A1 TREATMENTS AND METHODS FOR INCREASING DOPAMINE UNIV OXFORD INNOVATION LTD (GB) 2025-07-10 US disclosed
EP-4493171-A1 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) 2025-01-22 EP disclosed
WO-2023175357-A1 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-09-21 WO disclosed
US-20220033490-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2022-02-03 US disclosed
US-8980923-B2 Compositions and methods for selective inhibition of nicotine acetylcholine receptors UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-03-17 US disclosed
US-20090062339-A1 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-03-05 US disclosed
WO-2005032479-A3 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS UNVIVERSITY OF FLORIDA RES FOU (US) 2005-09-15 WO disclosed
US-20050119309-A1 Compositions and methods for selective inhibition of nicotine acetylcholine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-02 US disclosed
US-20050119309-A1 Compositions and methods for selective inhibition of nicotine acetylcholine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-02 US disclosed
WO-2005032479-A2 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS UNVIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2005-04-14 WO disclosed
WO-2005032479-A2 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS UNVIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062339-A1 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS CHRNA5, CHRNA6, CHRNA3 NAAA 653/4885DGKA 3465/4885GAA 3290/4885
US-20050119309-A1 Compositions and methods for selective inhibition of nicotine acetylcholine receptors CHRNA5, CHRNA6, CHRNA3 NAAA 653/4885DGKA 3465/4885GAA 3290/4885
US-20120329783-A1 COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS CHRNA5, CHRNA6, CHRNA3 NAAA 653/4885DGKA 3465/4885GAA 3290/4885
US-20220033490-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS CHRNA6, CHRNA1, CHRNB1 NAAA 576/4885DGKA 2074/4885GAA 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.